Advertisement

Impact of Tachyarrhythmia Detection Rate and Time from Detection to Shock on Outcomes in Nationwide US Practice

Published:September 01, 2017DOI:https://doi.org/10.1016/j.amjcard.2017.07.015
      Although higher detection rates and delayed detection improve survival in implantable cardioverter defibrillator clinical trials, their effectiveness in clinical practice has limited validation. To evaluate the effectiveness of programming strategies for reducing shocks and mortality, we conducted a nationwide assessment of patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators with linked remote monitoring data. We categorized patients based on the presence or absence of high rate detection and delayed detection: higher rate delayed detection (HRDD), higher rate early detection (HRED), lower rate delayed detection (LRDD), and lower rate early detection (LRED). Cox regression was used to compare mortality and shock-free survival. There were 64,769 patients (age 68 ± 12 years; 27% female; 46% cardiac resynchronization therapy defibrillator; follow-up 1.7 ± 1.1 years). In the first year, 13% of HRDD, 14% of HRED, 18% of LRDD, and 20% in the LRED group experienced a shock. After adjustment, HRDD was associated with lower risk of shock than HRED (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.89 to 0.98, p = 0.002), LRDD (HR 0.63, 95% CI 0.60 to 0.66, p <0.001), and LRED (HR 0.58, 95% CI 0.55 to 0.61, p <0.001). HRDD was also associated with lower risk of mortality than HRED (adjusted HR 0.80, 95% CI 0.75 to 0.86, p <0.001), LRDD (HR 0.76, 95% CI 0.70 to 0.83, p <0.001), and LRED (HR 0.68, 95% CI 0.62 to 0.73, p <0.001). Similar results were observed in patients with or without a shock in the first 6 months after implant. In conclusion, high rate programming is associated with lower risk of shocks or death compared with delayed detection. Optimal outcomes are observed in patients programmed with both high rate and delayed detection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
        A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
        N Engl J Med. 1997; 337: 1576-1583
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • Poole J.E.
        • Packer D.L.
        • Boineau R.
        • Domanski M.
        • Troutman C.
        • Anderson J.
        • Johnson G.
        • McNulty S.E.
        • Clapp-Channing N.
        • Davidson-Ray L.D.
        • Fraulo E.S.
        • Fishbein D.P.
        • Luceri R.M.
        • Ip J.H.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • Saeed M.
        • Hanna I.
        • Robotis D.
        • Styperek R.
        • Polosajian L.
        • Khan A.
        • Alonso J.
        • Nabutovsky Y.
        • Neason C.
        Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study.
        J Cardiovasc Electrophysiol. 2014; 25: 52-59
        • Moss A.J.
        • Schuger C.
        • Beck C.A.
        • Brown M.W.
        • Cannom D.S.
        • Daubert J.P.
        • Estes 3rd, N.A.
        • Greenberg H.
        • Hall W.J.
        • Huang D.T.
        • Kautzner J.
        • Klein H.
        • McNitt S.
        • Olshansky B.
        • Shoda M.
        • Wilber D.
        • Zareba W.
        • Investigators M.-R.T.
        Reduction in inappropriate therapy and mortality through ICD programming.
        N Engl J Med. 2012; 367: 2275-2283
        • Wilkoff B.L.
        • Williamson B.D.
        • Stern R.S.
        • Moore S.L.
        • Lu F.
        • Lee S.W.
        • Birgersdotter-Green U.M.
        • Wathen M.S.
        • Van Gelder I.C.
        • Heubner B.M.
        • Brown M.L.
        • Holloman K.K.
        • Investigators P.S.
        Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
        J Am Coll Cardiol. 2008; 52: 541-550
        • Gasparini M.
        • Proclemer A.
        • Klersy C.
        • Kloppe A.
        • Lunati M.
        • Ferrer J.B.
        • Hersi A.
        • Gulaj M.
        • Wijfels M.C.
        • Santi E.
        • Manotta L.
        • Arenal A.
        Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.
        JAMA. 2013; 309: 1903-1911
        • Schron E.B.
        • Exner D.V.
        • Yao Q.
        • Jenkins L.S.
        • Steinberg J.S.
        • Cook J.R.
        • Kutalek S.P.
        • Friedman P.L.
        • Bubien R.S.
        • Page R.L.
        • Powell J.
        Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.
        Circulation. 2002; 105: 589-594
        • Daubert J.P.
        • Zareba W.
        • Cannom D.S.
        • McNitt S.
        • Rosero S.Z.
        • Wang P.
        • Schuger C.
        • Steinberg J.S.
        • Higgins S.L.
        • Wilber D.J.
        • Klein H.
        • Andrews M.L.
        • Hall W.J.
        • Moss A.J.
        Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
        J Am Coll Cardiol. 2008; 51: 1357-1365
        • Silver M.T.
        • Sterns L.D.
        • Piccini J.P.
        • Joung B.
        • Ching C.K.
        • Pickett R.A.
        • Rabinovich R.
        • Liu S.
        • Peterson B.J.
        • Lexcen D.R.
        • Shock-Less I.
        Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
        Heart Rhythm. 2015; 12: 545-553
        • Tan V.H.
        • Wilton S.B.
        • Kuriachan V.
        • Sumner G.L.
        • Exner D.V.
        Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
        Circ Arrhythm Electrophysiol. 2014; 7: 164-170